Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2558-2568

  Uehara, Hisanori ^a   Takahashi, Tetsuyuki ^a   Oha, Mina ^a   Ogawa, Hirohisa ^a   Izumi, Keisuke ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Fatty acid binding protein 4; Invasion; Lung metastasis; Prostate cancer

Indexed keywords

CASPASE 3; FATTY ACID BINDING PROTEIN 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLEIC ACID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; [2' (5 ETHYL 3,4 DIPHENYL PYRAZOL 1 YL)BIPHENYL 3 YLOXY]; FABP4 PROTEIN, HUMAN; FATTY ACID; FATTY ACID BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DU145 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN TRANSPORT; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921650957     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28903     Document Type: Article

References (45)

1. Society AC. Cancer facts And figures 2012. Atlanta, GA: Amercian Cancer Society, 2012.
2. Fowke JH, Motley SS, Concepcion RS, et al. Obesity, body composition, and prostate cancer. BMC Cancer 2012;12:23.
3. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:1665-71.
4. Kristal AR, Gong Z. Obesity and prostate cancer mortality. Future Oncol 2007;3:557-67.
5. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
6. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
7. Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10:345-53.
8. Rundle A, Jankowski M, Kryvenko ON, et al. Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev 2013;22:898-904.
9. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892: 146-54.
10. Somasundar P, Yu AK, Vona-Davis L, et al. Differential effects of leptin on cancer in vitro. J Surg Res 2003;113:50-5.
11. Onuma M, Bub JD, Rummel TL, et al. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003;278:42660-7.
12. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-6.
13. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-65.
14. Freeman MR, Paul S, Kaefer M, et al. Heparinbinding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 1998;68: 328-38.
15. Torring N, Jorgensen PE, Sorensen BS, et al. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-5.
16. Senolt L, Polanska M, Filkova M, et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010;69:1410-1.
17. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13.
18. Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996;274:1377-9.
19. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002; 13:141-7.
20. Cousin B, Munoz O, Andre M, et al. A role for preadipocytes as macrophage-like cells. Faseb J 1999;13:305-12.
21. Makowski L, Brittingham KC, Reynolds JM, et al. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005;280:12888-95.
22. Richieri GV, Ogata RT, Zimmerman AW, et al. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 2000;39:7197-204.
23. Veerkamp JH, Peeters RA, Maatman RG. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991;1081:1-24.
24. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999;40:967-72.
25. Baar RA, Dingfelder CS, Smith LA, et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice Am J Physiol Endocrinol Metab 2005;288:E187-93.
26. Cabre A, Lazaro I, Girona J, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007;195:e150-8.
27. Hancke K, Grubeck D, Hauser N, et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119:367-7.
28. De Santis ML, Hammamieh R, Das R, et al. Adipocyte-fatty acid binding protein induces apoptosis in DU145 prostate cancer cells. J Exp Ther Oncol 2004;4:91-100.
29. Das R, Hammamieh R, Neill R, et al. Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin Cancer Res 2001;7:1706-15.
30. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009;124:1820-8.
31. Raucci R, Rusolo F, Sharma A, et al. Functional and structural features of adipokine family. Cytokine 2013;61:1-14.
32. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006;28:737-45.
33. Somasundar P, Frankenberry KA, Skinner H, et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res 2004;118:71-82.
34. Sulsky R, Magnin DR, Huang Y, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett 2007;17:3511-5.
35. Furuhashi M, Tuncman G, Gorgun CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-65.
36. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503.
37. Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 2001;22:701-7.
38. Bassett JK, Severi G, Hodge AM, et al. Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk. Int J Cancer 2001;133:1882-91.
39. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50: 6130-8.
40. Ribeiro AM, Andrade S, Pinho F, et al. Prostate cancer cell proliferation and angiogenesis in different obese mice models. Int J Exp Pathol 2010; 91:374-86.
41. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
42. Zhou H, Li XM, Meinkoth J, et al. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000;151:483-94.
43. Brumatti G, Salmanidis M, Ekert PG. Crossing paths: interactions between the cell death machinery and growth factor survival signals. Cell Mol Life Sci 2010;67:1619-30.
44. Shukla S, Maclennan GT, Hartman DJ, et al. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007;121:1424-32.
45. Hillman GG, Wang Y, Kucuk O, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004;3:1271-9.